Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00976)
Name	Cytarabine
Synonyms	Click to Show/Hide the Synonyms of This API cytarabine; 147-94-4; Cytosine arabinoside; Ara-C; Arabinocytidine; Cytosar; Tarabine; Udicil; Cytosar-U; 1-beta-D-Arabinofuranosylcytosine; Arabinofuranosylcytosine; DepoCyte; Cytarabin; Arabinosylcytosine; Aracytidine; Cytosine beta-D-arabinofuranoside; Cytosinearabinoside; Cytarabinoside; Citarabina; Cytarabinum; Alexan; Depocyt; beta-D-Arabinosylcytosine; Cytarabinum [INN-Latin]; Citarabina [INN-Spanish]; Cytosine-1-beta-D-arabinofuranoside; AraC; Cytosine beta-D-arabinoside; Spongocytidine; 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Arabitin; Aracytin; Cytarabina; Arafcyt; Erpalfa; Iretin; 1beta-D-Arabinosylcytosine; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; Cytosine arabinose; 1beta-Arabinofuranasylcytosine; Aracytine; Cytosine 1-beta-D-arabinofuranoside; 1beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; Cytosine-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Depocyt (liposomal); 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-; 1-beta-D-Arabinosylcytosine; Cytarabine free base; UNII-04079A1RDZ; Arabinoside C; (beta-D-Arabinofuranosyl)cytosine; MFCD00066487; CHEMBL803; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; AR3; Cytonal; 147-94-4 (free); CHEBI:28680; CHX 3311; 04079A1RDZ; 1-beta-D-arabinofuranosyl-cytosine; U-19920; CCRIS 913; Cytarabine, 98%; beta-Ara C; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; U 19920A; U-19,920; Cytosine, 1-beta-D-arabinosyl-; arabinocytosine; C9H13N3O5; HSDB 3049; NCGC00093356-03; 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; DSSTox_CID_2877; Cytosine, 1-beta-D-arabinofuranosyl-; NSC 287459; AC-1075; DSSTox_RID_76771; DSSTox_GSID_22877; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; AI3-52329; Cytosine arabinoside (VAN); 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-; beta-Arabinosylcytosine; Beta-cytosine arabinoside; Cytosine-beta-arabinoside; Ara-Cytidine; cytarabine liposome injection; Arabinosyl Cytosine; Cytosine, beta-D-arabinoside; CAS-147-94-4; SMR000449317; Depocyt (TN); EINECS 205-705-9; 1-(arabinofuranosyl)cytosine; Cytartbine; 1-beta-arabinofuranosylcytosine; SR-01000075773; NSC287459; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; NSC-287459; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 1-.beta.-D-arabinofuranosyl-cytosine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; Cytarabine [USAN:USP:INN:BAN:JAN]; MK 8242; PubChem14152; beta -arabinosylcytosine; 1-b-D-ribosyl-Cytosine; beta -cytosine arabinoside; beta -D-arabinosylcytosine; Cytosine-beta -arabinoside; SCHEMBL3140; 1-b-D-Ribofuranosylcytosine; 1beta -D-Arabinosylcytosine; BIDD:PXR0139; cytosine-1b-D-Ribofuranoside; Lopac0_000316; cc-278; MLS000758310; MLS001066340; MLS001424023; 1-beta-D-Arabinosyl-Cytosine; 1-beta-delta-ribosyl-Cytosine; BIDD:GT0371; Cytosine, beta -D-arabinoside; 1beta -Arabinofuranasylcytosine; Cytarabine (JP17/USP/INN); GTPL4827; PYR287; 1-ss-D-Arabinofuranosylcytosine; 1-beta-D-ribofuranosyl-Cytosine; cytosine-1b-delta-Ribofuranoside; DTXSID3022877; SCHEMBL22591193; 1beta-delta-Ribofuranosylcytosine; 1beta -D-Arabinofuranosylcytosine; Cytosine, 1-beta -D-arabinosyl-; 1-beta -d-arabinofuranosylcytosine; 1-beta-D-arabinofuranosyl cytosine; 1-beta-delta-Ribofuranosylcytosine; Cytosine-beta -D-arabinofuranoside; HMS2051K19; HMS2090A18; HMS2230M16; HMS3713N12; 1-beta -D-Arabinofaranosylcytosine; cytosine-1beta-delta-Ribofuranoside; 1-beta-delta-ribofuranosyl-Cytosine; BCP02876; ZINC3795098; Tox21_111203; Tox21_301971; ANW-58969; BDBM50087289; CCG-51297; EBD145460; s1648; (non-labelled)Cytarabine-13C-15N2; AKOS007930145; AKOS015896896; AM84428; Cytosine, 1-beta -D-arabinofuranosyl-; DB00987; KS-5063; MCULE-3945147956; NC00070; SDCCGSBI-0050304.P002; NCGC00093356-04; NCGC00093356-05; NCGC00093356-06; NCGC00093356-19; NCGC00142483-02; NCGC00255381-01; HY-13605; SRI-10828-19; SRI-10828-20; SRI-10828_24; AB0005212; SL-000002; SW197450-5; C02961; D00168; J10463; K-4708; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C; 10163-EP2272828A1; 10163-EP2284920A1; 10163-EP2287165A2; 10163-EP2287166A2; 10163-EP2292603A1; 10163-EP2292620A2; 10163-EP2298764A1; 10163-EP2298765A1; 10163-EP2298774A1; 10163-EP2299509A1; 10163-EP2301921A1; 10163-EP2301926A1; 10163-EP2301936A1; 10163-EP2308843A1; 10163-EP2314558A1; 10163-EP2316452A1; 10163-EP2371810A1; 10163-EP2372804A1; 10163-EP2378585A1; 15153-EP2270018A1; 15153-EP2272832A1; 15153-EP2275420A1; 15153-EP2277565A2; 15153-EP2277566A2; 15153-EP2277567A1; 15153-EP2277568A2; 15153-EP2277569A2; 15153-EP2277570A2; 15153-EP2277865A1; 15153-EP2292280A1; 15153-EP2295055A2; 15153-EP2295416A2; 15153-EP2295426A1; 15153-EP2295427A1; 15153-EP2298748A2; 15153-EP2298764A1; 15153-EP2298765A1; 15153-EP2298768A1; 15153-EP2298778A1; 15153-EP2298780A1; 15153-EP2301928A1; 15153-EP2305642A2; 15153-EP2305689A1; 15153-EP2308833A2; 15153-EP2308855A1; 15153-EP2308861A1; 15153-EP2311453A1; 15153-EP2311808A1; 15153-EP2311825A1; 15153-EP2311829A1; 15153-EP2311840A1; 15153-EP2311842A2; 15153-EP2314590A1; 15153-EP2316832A1; 15153-EP2316833A1; 15187-EP2270008A1; 15187-EP2280012A2; 15187-EP2281815A1; 15187-EP2292233A2; 15187-EP2292615A1; 15187-EP2292617A1; 15187-EP2301928A1; 15187-EP2301933A1; 15187-EP2305640A2; 15187-EP2305671A1; 15187-EP2308833A2; 15187-EP2311827A1; 15187-EP2311840A1; 15187-EP2316832A1; 15187-EP2316833A1; 147C944; 4-Amino-1-b-D-ribofuranosyl-2(1H)-pyrimidinone; Q180983; SR-01000721860; J-520199; J-700005; J-700166; SR-01000075773-3; SR-01000075773-5; SR-01000721860-6; 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl; BRD-K33106058-001-07-7; BRD-K33106058-003-20-6; 2(1H)-Pyrimidinone, 4-amino-1-; A-D-arabinofuranosyl-; 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-; 4-Amino-1-beta-delta-ribofuranosyl-2(1H)-pyrimidinone; Z1522566619; 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-; Cytarabine, European Pharmacopoeia (EP) Reference Standard; 1-(b-D-Ribofuranosyl)-2-oxo-4-amino-1,2-dihydro-1,3-diazine; Cytarabine, United States Pharmacopeia (USP) Reference Standard; Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC); 1-(b-delta-Ribofuranosyl)-2-oxo-4-amino-1,2-dihydro-1,3-diazine; Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%; Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
Clinical Status	Approved
PubChem CID	6253
Formula	C9H13N3O5
Canonical SMILES	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
InChI	1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKey	UHDGCWIWMRVCDJ-CCXZUQQUSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6253"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	243.22	Topological Polar Surface Area	129
	XlogP	-2.1	Complexity	383
	Heavy Atom Count	17	Rotatable Bond Count	2
	Hydrogen Bond Donor Count	4	Hydrogen Bond Acceptor Count	5

Full List of Drug Formulations (DFMs) Containing This API
Cytarabine 100mg/5ml solution			Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Sodium Chloride; Water; Hydrochloric Acid; Sodium Hydroxide
Dosage Form	Solution
Company	Gland Pharma Limited
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Hydrochloric acid	DIG Info	Carbonic anhydrase V (Ki = 156 nM)	[1]
Cytarabine 2g/20ml solution			Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Water; Hydrochloric Acid; Sodium Hydroxide
Dosage Form	Solution
Company	Hospira
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Hydrochloric acid	DIG Info	Carbonic anhydrase V (Ki = 156 nM)	[1]

References
1	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1; 14(21):5435-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.